Startups and Licensing
Intellectual property developed at the Wyss Institute is marketed by the Institute’s Business Development team, which works with Harvard’s Office of Technology Development to negotiate license agreements to existing companies or new startups. Some examples of our licensed technologies and startups are described below.
-
BOA Biomedical
Pathogen-capture
BOA Biomedical
BOA Biomedical is developing a pathogen-capture technology that physically removes bacteria, viruses, and other infectious agents from the blood. This system has the potential to save lives by treating or preventing life-threatening sepsis, buying extra time for critically ill patients to fight off diseases, and quickly identify pathogens so patients can be given the right treatment, thereby reducing the development of antibiotic resistance.
Translation News
Wyss Institute and Miraki Innovation Unveil BOA Biomedical to Reduce Sepsis Deaths
-
Sherlock Biosciences
Molecular diagnostics
Sherlock Biosciences
Sherlock Biosciences leverages the INSPECTR™ technology from the Wyss Institute to create a highly sensitive, nucleic acid-based diagnostic platform that can rapidly deliver accurate and inexpensive results for a vast range of needs in virtually any setting
Translation News
Sherlock Biosciences Licenses Wyss Technology to Create Affordable Molecular Diagnostics
-
ReadCoor
Spatial sequencing
ReadCoor
ReadCoor leverages the Wyss Institute’s Fluorescent in situ Sequencing method for simultaneously sequencing and mapping thousands of RNAs within cells and tissues to advance development of diagnostics and discover new drug targets.
Translation News
Wyss Institute launches ReadCoor to commercialize 3D in situ gene sequencing technology
-
Ultivue
DNA-based Imaging
Ultivue
Ultivue is developing innovative imaging solutions to unfold new areas of biology by leveraging the Institute’s DNA-PAINT technology. At the center of the technology is the transient binding of fluorophores to targets mediated by DNA-DNA interaction
Translation News
Ultivue Raises $22 Million in Series C Funding
Ultivue Inc. Announces Completion of its Series B Financing
Harvard’s Wyss Institute launches Ultivue to facilitate super-resolution microscopy
-
FitBiomics
Sports genomics
FitBiomics
FitBiomics utilizes next-generation sequencing to identify and isolate novel probiotic bacteria for applications in sports performance and recovery. Learn more about the Wyss Institute’s ‘Sports Genomics’ technology.
Translation News
Harvard’s athlete-based next-generation probiotics technology licensed to FitBiomics
Discovery of performance-enhancing bacteria in the human microbiome
-
Emulate
Organs-on-Chips
Emulate
Emulate leverages the Wyss Institute’s organs-on-chips technology to emulate human biology towards understanding how diseases, medicines, chemicals, and foods affect human health
Translation News
Founders Fund Leads $36 Million Financing Round in Emulate, Inc.
Organ-On-A-Chip Startup, Emulate, Grabs $45M to Shake Up Drug Discovery
Wyss Institute’s technology translation engine launches ‘Organs-on-Chips’ company
-
Root Robotics
Robots teaching kids to code
Root Robotics
Root Robotics, acquired by iRobot, is commercializing Root, an educational and interactive robot to teach coding to many age groups and experience levels
Translation News
iRobot Introduces the Root Coding Robot Through Acquisition of Root Robotics
10 amazing toys that can teach your kids how to code
This robot can help your kids learn to code
CES 2018: The Root aims to teach kindergartners how to code
TechRadar's 2018 CES Awards – the best tech at the show
Harvard’s Wyss Institute launches Root Robotics, an educational startup to get anyone coding
-
NuProbe
Nucleic acid diagnostics
NuProbe
NuProbe utilizes DNA toehold probe systems to develop non-invasive cancer and infectious disease diagnostics
Translation News
Harvard’s Wyss Institute launches NuProbe to facilitate global precision medicine
-
FreeFlow Medical Devices
Non-stick coatings for medical devices
FreeFlow Medical Devices
FreeFlow Medical Devices uses an anti-adhesive coating technology to eliminate the formation of biofilms and blood clots on the surfaces of medical devices.
Translation News
Bioinspired coating for medical devices repels blood and bacteria
-
Adaptive Surface Technologies
Slippery surfaces
Adaptive Surface Technologies
Adaptive Surface Technologies (formerly SLIPS Technologies, Inc.) leverages the Wyss Institute’s Slippery Liquid-Infused Porous Surfaces (SLIPS) technology to create a family of materials and coatings that repel virtually all fluids and biological fouling agents in industrial, medical, and consumer applications
Translation News
SLIPS Technologies Announces $8.6 Million in New Funding Round
-
MediCollector
Bedside data acquisition
MediCollector
MediCollector uses the Institute’s data acquisition algorithms to enable continuous collection of data to better characterize physiological changes and treatment in patients
Translation News
-
ReWalk Robotics
Soft exosuit for stroke
ReWalk Robotics
The Institute’s soft exosuit technology has been licensed by ReWalk Robotics, Ltd. towards further development of concepts and designs of lightweight exoskeleton system technologies for medical applications such as stroke and multiple sclerosis. Licensing opportunities are available for other soft exosuit applications.
Translation News
FDA Issues Clearance for the ReStore™ Exo-Suit, the First Soft Robotic System for Stroke Therapy
ReWalk Robotics Receives CE Mark for ReStore™ Exo-Suit Stroke Rehabilitation Device
Post-stroke patients reach terra firma with Wyss Institute’s exosuit technology